Quince Therapeutics announced Phase 2a data for LAM-001 in pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The 24-week open-label trial enrolled 10 adult patients across four U.S. sites. LAM-001 was added to standard of care.
In the PH-ILD subgroup, mean six-minute walk distance improved by 67.4 meters, and pulmonary vascular resistance decreased by 33.9%.
These results highlight the potential of LAM-001. Bond.az will continue to follow developments.
